Use of inductively coupled plasma-mass spectrometry in boron-10 stable isotope experiments with plants, rats, and humans.

por Vanderpool, R A, Hoff, D, Johnson, P E
Publicado 1994

Advances in the treatment of patients with pancreatic cancer: improvement in symptoms and survival time. The San Antonio Drug Development Team.

por Von Hoff, D. D., Goodwin, A. L., Garcia, L.
Publicado 1998

Human colon cancer cell lines secrete alpha TGF-like activity.

por Hanauske, A. R., Buchok, J., Scheithauer, W., Von Hoff, D. D.
Publicado 1987

Positron emission tomography (PET) as a predictive measure in patients with metastatic pancreatic cancer and normal CA19-9 levels at baseline

por Ramanathan, R. K., Korn, R. L., Chiorean, E. G., Liu, H., Von Hoff, D. D.
Publicado 2016

A polymer-based drug delivery system for the antineoplastic agent bis(maltolato)oxovanadium in mice.

por Jackson, J. K., Min, W., Cruz, T. F., Cindric, S., Arsenault, L., Von Hoff, D. D., Degan, D., Hunter, W. L., Burt, H. M.
Publicado 1997

A human breast cancer model for the study of telomerase inhibitors based on a new biotinylated-primer extension assay

por Raymond, E, Sun, D, Izbicka, E, Mangold, G, Silvas, E, Windle, B, Sharma, S, Soda, H, Laurence, R, Davidson, K, Hoff, D D Von
Publicado 1999

Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic a...

por Ramanathan, R. K., Goldstein, D., Korn, R. L., Arena, F., Moore, M., Siena, S., Teixeira, L., Tabernero, J., Van Laethem, J.-L., Liu, H., McGovern, D., Lu, B., Von Hoff, D. D.
Publicado 2016

CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients...

por Chiorean, E. G., Von Hoff, D. D., Reni, M., Arena, F. P., Infante, J. R., Bathini, V. G., Wood, T. E., Mainwaring, P. N., Muldoon, R. T., Clingan, P. R., Kunzmann, V., Ramanathan, R. K., Tabernero, J., Goldstein, D., McGovern, D., Lu, B., Ko, A.
Publicado 2016

Phase I, first-in-human study of MSC-1 (AZD0171), a humanized anti-leukemia inhibitory factor monoclonal antibody, for advanced solid tumors

por Borazanci, E., Schram, A.M., Garralda, E., Brana, I., Vieito Villar, M., Spreafico, A., Oliva, M., Lakhani, N.J., Hoffman, K., Hallett, R.M., Maetzel, D., Hua, F., Hilbert, J., Giblin, P., Anido, J., Kelly, A., Vickers, P.J., Wasserman, R., Seoane, J., Siu, L.L., Hyman, D.M., Hoff, D.V., Tabernero, J.
Publicado 2022